Large 'real-world' study of Pfizer's COVID-19 vaccine confirms efficacy across most age groups

Israel vaccinates against COVID-19
(Image credit: Jack Guez/AFP/Getty Images)

The Pfizer-BioNTech COVID-19 vaccine was basically as effective in a study of 600,000 Israelis as in Pfizer's smaller clinical trials, researchers reported Wednesday in the New England Journal of Medicine. And the new study provided evidence Pfizer was unable to show, due to limited data in its trials, that the vaccine is equally effective in people 70 and over as in younger people.

The publisher results provide "scientifically validated real-world evidence of the effectiveness of the vaccine," said Ran Balicer, one of the study's chief authors and chief innovation officer at Clalit, Israel's largest health care provider.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.